摘要
目的:探讨小剂量盐酸替罗非班在老年非ST段抬高型急性冠状动脉综合征(NSTEACS)药物保守治疗中的有效性及安全性。方法:选择96例诊断明确的NSTEACS老年患者,随机分成对照组和观察组。2组均给予阿司匹林、氯吡格雷、低分子肝素等药物治疗。在此基础上观察组给予小剂量替罗非班,比较2组治疗效果及安全性。结果:观察组用药后7d及30d复合心血管事件(顽固性心绞痛+再发心肌梗死+死亡)均减少(P<0.05)。观察组血小板聚集率降低更明显(P<0.01)。对照组和观察组主要不良事件均为出血,发生率分别为4.35%和6.0%(P>0.05)。结论:在非介入治疗老年NSTEACS患者中,小剂量替罗非班能有效加强抗血小板作用,不增加出血风险,与阿司匹林、氯吡格雷、低分子肝素合用是安全有效的。
Objective：To explore effects of low does of tilofiban in conservative treatment of elderly patients with non-ST-segment acute coronary syndromeis（NSTEACS）.Method：The 96elderly patients with diagnosed NSTEACS were divided into control group（n=46）and observation group（n=50）.All patients were given aspirin,clopidogrel and low molecular heparin.The observation group was added low does tilofiban after admission to hospital on the basis of conventional drug therapy.We compared the efficacy and adverse reactions between the two groups.Result：Compared with the control group,After 7dand 30d,the incidence of composite cardiovascular events（refractory angina pectoris,myocardial infarction again and death）in the observation group were all reduced（P0.05）.Platelet aggregation rate in observation group was decreased more obvious（P0.01）.The major adverse events in control group and observation group were bleeding,the incidence was 4.35% and 6.0% respectively（P0.05）.Conclusion：In the non-interventional therapy in elderly patients with NSTEACS,low dose of tilofiban can effectively strengthen the antiplatelet effect witout increased risk of bleeding.And it is safe and effective to shared with aspirin,clopidogrel,and low molecular heparin.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2014年第1期31-34,共4页
Journal of Clinical Cardiology
